📄 medicine

Medetomidine as a Fentanyl Adulterant: Pharmacology, Detection, Clinical Presentation, and Management

This review examines the emerging public health crisis of medetomidine as a fentanyl adulterant, detailing its distinct pharmacology, the severe withdrawal syndrome it causes, and the urgent need for improved detection, standardized management, and further research to address gaps in current clinical care.

Original authors: Kory S. London, Philip Durney, Brendan Hart, Ashish Thakrar, Dennis Goodstein, Alex J. Krotulski, Daniel Teixeira Silva, Joseph D’Orazio, Lara Carson Weinstein, Jeanmarie Perrone, Michael J. Lynch

Published 2026-08-27

📖 6 min read🧠 Deep dive

CC BY 4.0

Original authors: Kory S. London, Philip Durney, Brendan Hart, Ashish Thakrar, Dennis Goodstein, Alex J. Krotulski, Daniel Teixeira Silva, Joseph D’Orazio, Lara Carson Weinstein, Jeanmarie Perrone, Michael J. Lynch

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The street drugs sold in the United States have become a shifting landscape of danger, driven by a supply that is no longer just about a single substance but a chaotic mixture of chemicals added to extend effects or mimic them. For years, doctors and public health officials watched as a veterinary sedative called xylazine began appearing in illicit fentanyl, creating a new set of problems for patients, including severe skin wounds and a difficult withdrawal process. Now, a different chemical has begun to take its place in many cities, bringing with it a distinct and more aggressive set of challenges. This new player is medetomidine, a drug designed for animals that acts on the brain's nervous system to slow it down. Unlike its predecessor, this substance does not just cause sedation; it triggers a withdrawal syndrome so severe that it often requires intensive medical care, overwhelming hospital systems that were not built to handle it. Understanding how this chemical behaves, how it is detected, and how it is treated is no longer just a matter of forensic curiosity; it is a critical component of saving lives in a rapidly changing drug crisis.

A team of researchers, drawing on clinical experience from hospitals in Philadelphia and Pittsburgh alongside a review of available scientific literature, has mapped out the emergence of medetomidine as a dominant adulterant in the illicit drug supply. Their work reveals that while this chemical was first spotted in forensic samples in 2022, it spread with startling speed, appearing in drug samples across more than a dozen states within two years. In some regions, it has already displaced xylazine, becoming the primary non-opioid ingredient mixed with fentanyl. The researchers found that the clinical picture of medetomidine use is distinct from other sedatives. When a person overdoses on a mixture containing this drug, they may appear deeply sedated with a dangerously slow heart rate, yet their breathing often remains stable enough that standard overdose reversal drugs do not wake them up. The true danger, however, lies in what happens as the drug leaves the body. The withdrawal process begins quickly, often within hours of the last use, and is characterized by a violent rebound of the nervous system. Patients experience uncontrollable vomiting that resists standard anti-nausea medications, extreme spikes in blood pressure and heart rate, and a state of confusion that can mimic a seizure or a severe infection.

The study highlights that this withdrawal syndrome is unlike anything seen with traditional opioid withdrawal or even the withdrawal from xylazine. While opioid withdrawal makes a person feel sick and anxious, it rarely causes the extreme autonomic instability seen here. The researchers observed that patients suffering from medetomidine withdrawal often require admission to intensive care units, where they need powerful intravenous medications to calm their nervous systems. The standard treatments used for opioid withdrawal, such as clonidine, are sometimes insufficient on their own, forcing doctors to escalate to the use of dexmedetomidine, a closely related drug that is the active component of medetomidine but is approved for human use in hospital settings. This escalation is necessary because the body's reaction to the absence of the drug is so intense that oral medications often cannot be kept down, and the symptoms progress too rapidly for slower-acting treatments to work.

One of the key findings of the review is that the severity of the withdrawal appears to depend on both how common the drug is in a local area and how much of it is actually in the drug mixture itself. In cities like Philadelphia and Pittsburgh, where the drug has become widespread and concentrated, hospitals have seen a dramatic rise in admissions for severe withdrawal, with some data showing a tenfold increase in intensive care charges for these cases. In contrast, regions where the drug is present but less common have not yet seen the same surge in severe withdrawal cases, suggesting that a certain threshold of exposure is needed for the body to develop this specific, severe dependence. The researchers also noted that the drug is difficult to detect with standard hospital tests, which often miss it entirely, leading to delays in diagnosis. Because the drug is not yet a federally controlled substance and is not included in routine toxicology screens, many patients are treated based on the pattern of their symptoms rather than a confirmed chemical test.

The paper also addresses the complexities of treating pregnant patients and newborns exposed to the drug, noting that the risks of untreated withdrawal are high enough to warrant aggressive medical intervention, even though data on the long-term effects on the fetus remains limited. For the broader population, the emergence of this syndrome has exposed a gap in the healthcare system, where the line between behavioral health and acute medical care has become blurred. Patients who need intensive medical monitoring for their physical symptoms are often turned away from behavioral health centers that are not equipped to handle such severe physiological distress, yet they are also not always suited for standard emergency rooms that lack the specific protocols for this type of withdrawal. The researchers conclude that managing this crisis requires a new approach that integrates addiction medicine with critical care, developing specialized protocols and training for a condition that did not exist in hospitals just a few years ago.

The authors emphasize that while the spread of medetomidine is a serious public health threat, the solution lies in better detection, more effective treatment strategies, and a deeper understanding of how different chemical adulterants shape the experience of addiction and withdrawal. They call for more research to validate tools that can measure the severity of this specific withdrawal and to develop better ways to support patients as they move from the hospital back into the community. Until then, the medical community must rely on the patterns they have observed: a rapid onset of severe symptoms, a need for intensive care, and a treatment plan that goes far beyond what is typically used for opioid addiction. The story of medetomidine is a reminder that the illicit drug supply is dynamic and unpredictable, and that the medical response must be equally agile to protect those caught in its wake.

Technical Summary: Medetomidine as a Fentanyl Adulterant

Problem Statement
The illicit drug supply in the United States has undergone a rapid shift from fentanyl adulterated with xylazine to fentanyl adulterated with medetomidine, a more potent veterinary $\alpha_2$ -adrenergic agonist. Since its first detection in forensic samples in 2022, medetomidine has spread across North America, displacing xylazine in key markets such as Philadelphia and Pittsburgh. While xylazine was associated with distinct wound complications and a debated withdrawal syndrome, medetomidine presents a qualitatively different clinical challenge: a severe, rapidly progressive withdrawal syndrome characterized by autonomic dysregulation, intractable vomiting, and encephalopathy. This syndrome has overwhelmed existing clinical protocols, which were designed for opioid or xylazine withdrawal, and has exposed significant gaps in toxicology detection, withdrawal assessment, and integrated addiction-critical care models.

Methodology
This narrative systematic review synthesizes literature on medetomidine as an illicit adulterant from January 2015 through August 2026. The authors searched PubMed, Scopus, and Google Scholar using terms including "medetomidine," "fentanyl," "adulterant," "withdrawal," and "alpha-2 agonist." Due to the publication lag inherent in emerging public health crises, the authors supplemented peer-reviewed literature with "grey literature" from local and national sources, including CDC field reports, public health alerts, and drug-checking data.

The review included:

18 original clinical studies (case reports, series, and retrospective analyses).
4 CDC field reports.
5 forensic and drug-checking studies.
14 public health surveillance reports.
18 pharmacology and pharmacokinetic studies.
9 reviews, commentaries, and editorials.
5 guidelines and consensus statements.

The authors utilized the Scale for the Assessment of Narrative Review Articles (SANRA) to guide their approach. Where peer-reviewed evidence was thin, the authors drew upon clinical experience from Philadelphia and Pittsburgh, two of the most affected regions.

Key Contributions and Results

1. Pharmacology and Potency
Medetomidine is a racemic 1:1 mixture of the active S-(+)-enantiomer (dexmedetomidine) and the inactive R-(−)-enantiomer. Unlike xylazine, medetomidine exhibits:

Higher Selectivity: An $\alpha_2:\alpha_1$ selectivity ratio of ~1620:1 (compared to ~160:1 for xylazine).
Greater Potency: Approximately 200 times more potent than xylazine as an $\alpha_2$ agonist.
Imidazoline-1 (I1) Activity: Like clonidine, medetomidine binds to I1 receptors, a property xylazine lacks. This activity is hypothesized to contribute to the prolonged sympatholytic effects and the severe autonomic rebound seen in withdrawal.
Pharmacokinetics: The active enantiomer has an elimination half-life of 2–3 hours in healthy adults (2–4 hours in critically ill patients). Illicit samples contain the racemic mixture, which is not FDA-approved for human use.

2. Detection and Epidemiology

Spread: Medetomidine was first detected in Maryland (2022) and rapidly expanded to over 26 states and the District of Columbia by late 2025. In Philadelphia, it replaced xylazine as the dominant adulterant, rising from negligible levels to 88% of fentanyl-primary samples by late 2025.
Detection Limitations: Medetomidine is not included in standard hospital toxicology immunoassays, delaying diagnosis. Forensic identification relies on mass spectrometry. Enantiomeric differentiation (racemic vs. pure dexmedetomidine) is a key forensic marker distinguishing illicit use from iatrogenic exposure. New ICD-10-CM codes for medetomidine toxicity are scheduled for implementation in October 2026.

3. Acute Intoxication
Acute presentation involves opioid-mediated respiratory depression (reversible with naloxone) followed by a distinct phase of prolonged deep sedation, sinus bradycardia, and hypotension/normotension that persists despite adequate ventilatory drive. Unlike xylazine, medetomidine intoxication is less associated with necrotic skin wounds. Management is supportive; naloxone should be titrated to respiratory effort, not arousal, as medetomidine sedation is naloxone-resistant.

4. Withdrawal Syndrome
The dominant clinical problem is a severe withdrawal syndrome that differs significantly from opioid or xylazine withdrawal:

Onset: Begins 4–6 hours after last use, earlier than traditional opioid withdrawal.
Symptoms: Characterized by anxiety, diaphoresis, and rapidly escalating autonomic instability (tachycardia >180 bpm, systolic BP >240 mmHg). A hallmark feature is intractable vomiting refractory to standard antiemetics (e.g., ondansetron).
Neurological: A subset of patients develops hypoactive delirium, encephalopathy, and myoclonic jerking, which can mimic sepsis or seizures.
Severity: Existing tools like the Clinical Opiate Withdrawal Scale (COWS) underestimate severity in patients with hypoactive delirium.
ICU Utilization: In affected regions, ICU admissions for opioid withdrawal have risen sharply, with nearly 32% of OUD-related hospitalizations in Philadelphia involving dexmedetomidine administration by Q3 2025.

5. Management Strategies
The paper outlines a multimodal management approach:

Anti-emetics: Aggressive control of vomiting is prerequisite to oral therapy; dopamine antagonists (e.g., prochlorperazine, olanzapine) are preferred over ondansetron.
$\alpha_2$ -Agonist Therapy: The cornerstone of treatment. High-dose oral clonidine (titrated to HR/BP), often combined with guanfacine, tizanidine, or transdermal patches.
Parenteral Dexmedetomidine: Required when oral therapy fails or vomiting precludes administration. Infusions often require rates up to 2.5 mcg/kg/hr (exceeding standard ICU limits) and last 24–72 hours.
Opioid Management: Concurrent management of opioid withdrawal is essential. However, initiating buprenorphine based solely on COWS scores during the early $\alpha_2$ -withdrawal phase risks precipitating opioid withdrawal if residual fentanyl is present. Methadone or micro-dose buprenorphine induction is recommended.
Special Populations: Pregnant patients require aggressive management to prevent fetal distress; clonidine is the preferred agent. Neonatal exposure requires monitoring for autonomic instability, though specific protocols are not yet established.

Significance and Claims
The authors claim that medetomidine represents a distinct clinical entity from previous adulterants like xylazine. Its emergence highlights that the clinical consequences of an adulterant depend on specific receptor pharmacology (potency, selectivity, and I1 activity) rather than just drug class.

The paper posits that the emergence of severe withdrawal in specific regions (e.g., Philadelphia, Pittsburgh) but not others is likely driven by a combination of local prevalence thresholds and drug concentration. The syndrome exposes critical gaps in the healthcare system:

Diagnostic Gaps: The lack of rapid toxicology testing delays appropriate diagnosis.
Assessment Gaps: Existing withdrawal scales fail to capture the severity of $\alpha_2$ -agonist withdrawal, particularly in encephalopathic patients.
Systemic Gaps: The syndrome strains the coordination between behavioral health and physical health/critical care systems, as standard behavioral health centers are ill-equipped to manage the high-acuity physiological instability, while emergency departments are overwhelmed.

The authors conclude that prospective multicenter research, validated withdrawal instruments specific to $\alpha_2$ -agonists, and integrated addiction-critical care models are urgently needed to address this evolving public health crisis. They emphasize that the current treatment protocols developed for the xylazine era are insufficient for medetomidine-associated withdrawal.

Technical Summary: Medetomidine as a Fentanyl Adulterant

More like this